Experts break down key gastrointestinal cancer data and trends from the 2026 ESMO Congress.
News|Articles|November 12, 2026
GI Cancer Monthly Rewind: Key News and Expert Insights You May Have Missed in October 2026
Author(s)OncLive Staff
Fact checked by: Ashling Wahner
Check out this October recap of OncLive’s coverage of the top news and expert insights in gastrointestinal cancers.
Advertisement
Advertisement
October brought 2 FDA approvals in mismatch repair–deficient colon and rectal cancers, a run of expedited designations and international regulatory actions, phase 3 data from the 2026 European ESMO Congress (ESMO 2026) in pancreatic and gastric cancers, and expert perspectives on immunotherapy and MEK inhibition.
Related to this article
The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.
Lirafugratinib was added as a category 2A subsequent-line option for cholangiocarcinoma with an FGFR2 fusion or rearrangement and disease progression.
Dana-Farber, Mass General Brigham, and Broad Institute researchers uncovered clues to why colorectal cancer can be more aggressive in younger people.
First results from the phase 2 AZUR-1 trial showed sustained clinical complete responses with dostarlimab alone, sparing most patients chemoradiation and surgery.
The FDA approved talazoparib plus enzalutamide in HRR-mutated prostate cancer, ivonescimab improved survival in biliary tract cancer, and more.
Fox Chase researchers identified ANO6 as a potential pancreatic cancer target; blocking it slowed tumor growth and reduced immune suppression in preclinical studies.
Breakthroughs with daraxonrasib in pancreatic cancer pave the way for continued investment in understanding the fundamental biology of cancers.
Advertisement
Advertisement